Rep. Guthrie Introduces MVP Act to Link Medicaid Drug Payments to Patient Outcomes
This bill is currently sitting in the House committees where it was sent on March 8, 2026. Nothing has happened with the bill for four months, and it is not moving forward. A similar version of this bill exists in the Senate, but that version is also not advancing.
Companion bill: Sen. Mullin Pushes Bipartisan MVP Act to Only Pay for Medicaid Drugs if They Actually Work →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Smaller pharmaceutical and biotech companies developing high-cost therapies like gene treatments would benefit from clearer rules around value-based pricing. The bill removes legal uncertainty about anti-kickback laws and price reporting, making it easier for these companies to offer performance-based deals to Medicaid without risking compliance violations.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
The Medicaid VBPs for Patients (MVP) Act is intended to codify current Medicaid rules that permit the use of varying 'best price' points under voluntary, value-based state purchasing arrangements for curative cell and gene therapies, ensuring taxpayers aren't on the hook for ineffective treatments.
This report covers the regulatory foundation of the MVP Act, specifically the CMS rule allowing multiple best prices in Medicaid. The rule was intended to encourage drug manufacturers to enter into value-based agreements by protecting them from triggering a single low 'best price' across the board.
Coverage of the AMCP annual meeting highlights the MVP Act as a critical tool for modernizing the Medicaid payment framework. The bill allows manufacturers to report multiple best prices, facilitating outcomes-based contracts for expensive cell and gene therapies.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
MVP Act
Analysis generated by AI. Always verify with official sources.